A significant communication gap exists between NMIBC patients and providers, with only 18% having regular discussions about ...

The FDA approved pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph in combination with enfortumab vedotin-ejfv ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug ...

Merck (MRK) announced that the U.S. FDA has approved Keytruda and Keytruda Qlex in combination with Padcev as neoadjuvant treatment and then ...

(TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the U.S. Food and Drug Administration (FDA) has approved PADCEV (R) (enfortumab vedotin-ejfv), a Nectin-4 directed ...

Pfizer Inc. and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the U.S. Food and Drug Administration (FDA) has approved PADCEV® (enfortumab vedotin ...

Keytruda and Padcev improve event-free and overall survival for adults with muscle invasive bladder cancer who cannot receive ...

The FDA approved enfortumab vedotin and pembrolizumab for MIBC, following a priority review of their sBLA for neoadjuvant and ...

There are many different types of cysts that can develop on the ovary, ...

Bladder cancer ranks among the ten most common types of cancer worldwide. The main treatment is bladder removal surgery, and ...

The FDA recently approved a pretzel-shaped implant that helps some bladder cancer patients keep their bladder. Dr. Chris ...

Bladder cancer is often treated by removing visible tumors and using a type of immunotherapy called BCG, delivered through a ...